Compare Quest Diagnostics Inc (DGX) vs General Mills, Inc. (GIS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs General Mills, Inc. — how do they compare? Quest Diagnostics Inc trades at $204.5 (market cap $22.80B), while General Mills, Inc. trades at $36.92 (market cap $19.46B). The key difference: Quest Diagnostics Inc is the larger of the two by market cap, and General Mills, Inc. pays the higher dividend (6.69%). Which is the better fit depends on your goals.
| DGX | GIS | |
|---|---|---|
Market Cap | $22.80B | $19.46B |
Sector | Health | Consumer Staples |
52-Week High | $216.02 | $51.27 |
52-Week Low | $166.42 | $32.17 |
Enterprise Value | $28.82B | $32.95B |
Dividend Yield | 1.67% | 6.69% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $207.35, showing minimal daily movement with a slight decline of 0.04%. The stock maintains a bullish technical stance with recent earnings beats and analyst consensus pointing to upside potential. Recent developments include New York State approval for Haystack MRD testing and strong momentum across diagnostic channels. Revenue growth accelerated to $11.04 billion in 2025 with consistent profitability margins around 9%.
DGX presents a balanced investment case with 38% analyst buy ratings and a $227.75 price target suggesting 10% upside. The company demonstrates steady revenue growth and operational efficiency, though elevated debt levels and policy risks require monitoring. Second quarter earnings on July 23, 2026, will be crucial for validating current momentum and growth trajectory.
General Mills (GIS) trades at $36.60, up 1.05% with a bullish technical signal. The stock shows mixed earnings performance with recent Q2 2026 beating estimates, but faces declining revenue and negative net income margin. Analyst consensus is predominantly hold with a $36.14 price target. Cash flow trends show modest improvement, though debt levels have risen to 45% of assets. Recent news highlights cost-saving initiatives and innovation focus amid soft consumer demand.
Outlook remains cautious due to sales pressure and margin challenges, but valuation at 9.23 P/E suggests potential value. Key opportunities include $3 billion savings target by 2030 and brand investments. Risks involve persistent demand weakness, private label competition, and high debt burden. Investors should weigh cost-cutting benefits against top-line headwinds for recovery prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About General Mills, Inc.
General Mills is a leading global packaged food company that produces snacks, cereal, convenient meals, yogurt, dough, baking mixes and ingredients, pet food, and superpremium ice cream. Its largest brands are Nature Valley, Cheerios, Old El Paso, Yoplait, Pillsbury, Betty Crocker, BLUE, and Haagen-Dazs. In fiscal 2022, 77% of its revenue was derived from the United States, although the company also operates in Canada, Europe, Australia, Asia, and Latin America. While most of General Mills' products are sold through retail stores to consumers, the company also sells products into the food-service channel and the commercial baking industry.
Read more on GIS →
